Chondrogenic Potential of Periosteum-Derived Cells
Transfusion Medicine and Hemotherapy · 28.05.2026 · 1-12
DOI: 10.1159/000552725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion Medicine and Hemotherapy, online erschienen am 28.05.2026. Verfasst von Sarah Hochmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Experimental and Clinical Cell Therapy, Paracelsus Medical Private University Salzburg, Salzburg, Austria. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Successful bone regeneration after dental and craniofacial reconstruction can present a significant clinical challenge. In this study, we investigated whether the regenerative potential of human periosteum-derived stromal progenitor cells (PDCs) depends on their anatomical origin.
Methods
Paired periosteum samples were collected from jaw and appendicular bones (fibula, femur, or iliac crest) of five donors and expanded in a xeno-free, platelet lysate-supplemented medium. All cultures exhibited a typical fibroblastic morphology and a uniform stromal immunophenotype (≥95% CD73/90/105 and ≤2% CD45/14/19/HLA-DR). PDCs were tested in a 3D cartilage disc formation assay after seeding on collagen-coated transwell inserts or on transferrable porcine collagen membranes.
Results
Appendicular-derived PDCs consistently formed stable, cartilage-like 3D discs with a mean weight of 14.7 mg and a range of 8.8–23.6 mg, whereas jaw-derived PDCs produced contracted, irregular aggregates. Histological and molecular analyses confirmed greater proteoglycan deposition and higher COL2A1 expression in appendicular-derived PDCs, indicating superior intrinsic chondrogenic potential. Culturing jaw-derived PDCs on porcine collagen membranes did not enhance their differentiation capacity.
Conclusion
Our findings demonstrate that the chondrogenic potential of PDCs is strongly determined by their anatomical origin. Therefore, selecting the appropriate periosteal source, combined with optimized biomaterials, is crucial for achieving predictable and efficient bone regeneration.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Experimental and Clinical Cell Therapy, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
- Institute for Transfusion Medicine, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
- Department of Oral and Maxillofacial Surgery, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
- Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Julius Wolff Institute, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Berlin Center for Advanced Therapies (BECAT), Charité - Universitätsmedizin Berlin, Berlin, Germany.
Zitieren
APA
Hochmann, S., Brachtl, G., Poupardin, R., Hoog, A., Mittermeir, M., Raninger, A. M., Schallmoser, K., Wittig, J., Textor, M., Geissler, S., Gaggl, A., & Strunk, D. (2026). Chondrogenic Potential of Periosteum-Derived Cells. Transfusion Medicine and Hemotherapy, 1-12. https://doi.org/10.1159/000552725
Vancouver
Hochmann S, Brachtl G, Poupardin R, Hoog A, Mittermeir M, Raninger AM, et al. Chondrogenic Potential of Periosteum-Derived Cells. Transfusion Medicine and Hemotherapy. 2026:1-12. doi:10.1159/000552725
BibTeX
@article{Hochmann2026,
author = {Hochmann, Sarah and Brachtl, Gabriele and Poupardin, Rodolphe and Hoog, Anna and Mittermeir, Michaela and Raninger, Anna Maria and Schallmoser, Katharina and Wittig, Jörn and Textor, Martin and Geissler, Sven and Gaggl, Alexander and Strunk, Dirk},
title = {Chondrogenic Potential of Periosteum-Derived Cells},
journal = {Transfusion Medicine and Hemotherapy},
year = {2026},
pages = {1--12},
doi = {10.1159/000552725}
}
EUVIMED